Voltage-gated calcium channels are not affected by the novel anti-epileptic drug lacosamide

Translational Neuroscience

Volumn 2, Issue 1, 2011, Pages 13-22

  Wang, Yuying ^a,b   Khanna, Rajesh ^a,b  

^a Department of Pharmacology and Toxicology ^*  (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CAD cells; CaV2.2 N type Ca2+ channels; Hippocampal neurons; L type Ca2+ channels; Lacosamide

Indexed keywords

CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CALCIUM CHANNEL P TYPE; CALCIUM CHANNEL Q TYPE; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; HARKOSERIDE; VOLTAGE GATED CALCIUM CHANNEL;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CALCIUM CURRENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 79959255123     PISSN: 20813856     EISSN: 20816936     Source Type: Journal    
DOI: 10.2478/s13380-011-0002-9     Document Type: Article

References (57)

1. Llinas R.R., Intrinsic neuronal ectroresponsiveness and its possible role in epileptogenesis. Funct. Neurol. 1986, 1, 333-337 (Pubitemid 17119592)
2. Czapinski P., Blaszczyk B., Czuczwar S.J., Mechanisms of action of antiepileptic drugs. Curr. Top. Med. Chem. 2005, 5, 3-14 (Pubitemid 40202106)
3. Beyreuther B.K. et al., Lacosamide: a review of preclinical properties. CNS. Drug Rev. 2007, 13, 21-42 (Pubitemid 46697839)
4. Beydoun A., D'Souza J., Hebert D., Doty P., Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partialonset seizures. Expert. Rev. Neurother. 2009, 9, 33-42
5. Errington A.C., Stohr T., Heers C., Lees G., The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol. Pharmacol. 2008, 73, 157-169 (Pubitemid 350294207)
6. Sheets P.L., Heers C., Stoehr T., Cummins T.R., Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-thoxypropanamide], lidocaine, and carbamazepine. J. Pharmacol. Exp. Ther. 2008, 326, 89-99 (Pubitemid 351872141)
7. Park K.D. et al., Lacosamide isothiocyanate-based agents: novel agents to target and identify lacosamide receptors. J. Med. Chem. 2009, 52, 6897-6911
8. Goshima Y., Nakamura F., Strittmatter P., Strittmatter S.M., Collapsininduced growth cone collapse mediated by an intracellular protein related to UNC-33. Nature. 1995, 376, 509-514
9. Wang L.H., Strittmatter S.M., A family of rat CRMP genes is differentially expressed in the nervous system. J. Neurosci. 1996, 16, 6197-6207 (Pubitemid 26313994)
10. Schmidt E.F., Strittmatter S.M., The CRMP family of proteins and their role in Sema3A signaling. Adv. Exp. Med. Biol. 2007, 600:1-11., 1-11
11. Cavazos J.E., Cross D.J., The role of synaptic reorganization in mesial temporal lobe epilepsy. Epilepsy Behav. 2006, 8, 483-493
12. Czech T. et al., Reduction of hippocampal collapsin response mediated protein-2 in patients with mesial temporal lobe epilepsy. Neurochem. Res. 2004, 29, 2189-2196 (Pubitemid 40036890)
13. Ryu M.J., Lee C., Kim J., Shin H.S., Yu M.H., Proteomic analysis of stargazer mutant mouse neuronal proteins involved in absence seizure. J. Neurochem. 2008, 104, 1260-1270 (Pubitemid 351293351)
14. Brittain J.M. et al., An atypical role for CRMP-2 in neurotransmitter release via interaction with presynaptic Ca2+ channels. Neuroscience Meeting Planner. 519.4/C73. 2009. Chicago, IL: Society for Neuroscience, 2009.
15. Catterall W.A., Few A.P., Calcium channel regulation and presynaptic plasticity. Neuron. 2008, 59, 882-901
16. Dodge F.A., Jr., Rahamimoff R., On the relationship between calcium concentration and the amplitude of the end-plate potential. J. Physiol. 1967, 189, 90P-92P
17. Rahamimoff R., Dodge F.A., Jr. Regulation of transmitter release at the neuromuscular synapse: the cooperative hypothesis. Electroencephalogr. Clin. Neurophysiol. 1969, 27, 219
18. Llinas R.R., Calcium in synaptic transmission. Sci. Am. 1982, 247, 56-65 (Pubitemid 13249029)
19. Gargus J.J., Genetic calcium signaling abnormalities in the central nervous system: seizures, migraine, and autism. Ann. N. Y. Acad. Sci. 2009, 1151:133-56., 133-156
20. Jen J.C. et al., Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain. 2007, 130, 2484-2493 (Pubitemid 47511698)
21. Goslin K., Banker G., Experimental observations on the development of polarity by hippocampal neurons in culture. J. Cell Biol. 1989, 108, 1507-1516 (Pubitemid 19097054)
22. 2+ channels. J. Biol. Chem. 2009, 284, 31375-31390
23. Wang Y., Brittain J.M., Wilson S.M., Khanna R., Emerging roles of collapsin response mediator proteins (CRMPs) as regulators of voltage-gated calcium channels and synaptic transmission. Communicative & Integrative Biology 2010, 3, 1-4
24. Chen Y. et al., NS21: re-defined and modified supplement B27 for neuronal cultures. J. Neurosci. Methods. 2008, 171, 239-247
25. Wang Y. et al., In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein 2 (CRMP-2) identifies a pocket important in modulating sodium channel slow inactivation. J. Biol. Chem. 2010, 285, 25296-25307
26. Lorenzon N.M., Foehring R.C., Characterization of pharmacologically identified voltage-gated calcium channel currents in acutely isolated rat neocortical neurons. II. Postnatal development. J. Neurophysiol. 1995, 73, 1443-1451
27. Lees G., Stohr T., Errington A.C., Stereoselective effects of the novel anticonvulsant lacosamide against 4-AP induced epileptiform activity in rat visual cortex in vitro. Neuropharmacology. 2006, 50, 98-110 (Pubitemid 43069776)
28. Errington A.C., Coyne L., Stohr T., Selve N., Lees G., Seeking a mechanism of action for the novel anticonvulsant lacosamide. Neuropharmacology. 2006, 50, 1016-1029 (Pubitemid 43794912)
29. Chi X.X. et al., Regulation of N-type voltage-gated calcium (CaV2.2) channels and transmitter release by collapsin response mediator protein-2 (CRMP-2) in sensory neurons. J. Cell Sci. 2009, 23, 4351-4362
30. Grimm C., Holter N.I., Draguhn A., Bruehl C., Compensatory increase in P/Q-calcium current-mediated synaptic transmission following chronic block of N-type channels. Neurosci. Lett. 2008, 442, 44-49
31. Takahashi K., Wakamori M., Akaike N., Hippocampal CA1 pyramidal cells of rats have four voltage-dependent calcium conductances. Neurosci. Lett. 1989, 104, 229-234 (Pubitemid 19225618)
32. 2+ currents in isolated rat hippocampal CA1 pyramidal neurons. J. Neurophysiol. 1991, 65, 148-155
33. Newcomb R. et al., Selective peptide antagonist of the class E calcium channel from the venom of the tarantula Hysterocrates gigas. Biochemistry. 1998, 37, 15353-15362 (Pubitemid 28515996)
34. 2+ channels in rat isolated hippocampal CA1 pyramidal neurones. Br. J. Pharmacol. 1990, 100, 705-710 (Pubitemid 20233306)
35. Chameau P., Lucas P., Melliti K., Bournaud R., Shimahara T., Development of multiple calcium channel types in cultured mouse hippocampal neurons. Neuroscience. 1999, 90, 383-388 (Pubitemid 29161388)
36. Wang H., Oxford G.S., Voltage-dependent ion channels in CAD cells: A catecholaminergic neuronal line that exhibits inducible differentiation. J. Neurophysiol. 2000, 84, 2888-2895
37. Igelmund P., Zhao Y.Q., Heinemann U., Effects of T-type, L-type, N-type, P-type, and Q-type calcium channel blockers on stimulusinduced pre- and postsynaptic calcium fluxes in rat hippocampal slices. Exp. Brain Res. 1996, 109, 22-32 (Pubitemid 26119962)
38. Errington A.C., Stohr T., Lees G., Voltage gated ion channels: targets for anticonvulsant drugs. Curr. Top. Med. Chem. 2005, 5, 15-30 (Pubitemid 40202107)
39. Byk T., Dobransky T., Cifuentes-Diaz C., Sobel A., Identification and molecular characterization of Unc-33-like phosphoprotein (Ulip), a putative mammalian homolog of the axonal guidance-associated unc-33 gene product. J. Neurosci. 1996, 16, 688-701
40. Kodama Y. et al,. Induction of CRMP-2 by GDNF and analysis of the CRMP-2 promoter region. Biochem. Biophys. Res. Commun. 2004, 320, 108-115 (Pubitemid 38781790)
41. Kanter-Schlifke I., Georgievska B., Kirik D., Kokaia M., Seizure suppression by GDNF gene therapy in animal models of epilepsy. Mol. Ther. 2007, 15, 1106-1113 (Pubitemid 46813613)
42. (2+) channels and transmitter release. Neuron. 2001, 32, 99-112
43. ++ changes elicited by K+ and glutamate in single cultured neocortical neurons. Neurochem. Int. 1996, 29, 247-253 (Pubitemid 26270754)
44. Tokunaga T. et al., Pharmacological dissection of calcium channel subtype-related components of strontium inflow in large mossy fiber boutons of mouse hippocampus. Hippocampus. 2004, 14, 570-585 (Pubitemid 39107012)
45. Miyazaki K., Ishizuka T., Yawo H., Synapse-to-synapse variation of calcium channel subtype contributions in large mossy fiber terminals of mouse hippocampus. Neuroscience. 2005, 136, 1003-1014 (Pubitemid 41790516)
46. (2+) channel currents, altered synaptic transmission, and progressive ataxia in mice lacking the alpha(1A)-subunit. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 15245-15250 (Pubitemid 30019797)
47. (2+) Channels in Absence Epilepsy and in the Action of Ethosuximide. Epilepsy Curr. 2002, 2, 57
48. Lacinova L., Pharmacology of recombinant low-voltage activated calcium channels. Curr. Drug Targets. CNS. Neurol. Disord. 2004, 3, 105-111 (Pubitemid 38854905)
49. Macdonald R.L., Kelly K.M., Antiepileptic drug mechanisms of action. Epilepsia. 1993, 34 Suppl 5:S1-8., S1-S8 (Pubitemid 23249438)
50. Zamponi G.W., Lory P., Perez-Reyes E., Role of voltage-gated calcium channels in epilepsy. Pflugers Arch. 2010, 460, 395-403
51. Beyreuther B.K., Geis C., Stohr T., Sommer C., Antihyperalgesic efficacy of lacosamide in a rat model for muscle pain induced by TNF. Neuropharmacology. 2007, 52, 1312-1317 (Pubitemid 46527705)
52. Beyreuther B.K. et al. Antinociceptive efficacy of lacosamide in rat models for tumor- and chemotherapy-induced cancer pain. Eur. J. Pharmacol. 2007, 565, 98-104 (Pubitemid 46782774)
53. Stohr T., Krause E., Selve N., Lacosamide displays potent antinociceptive effects in animal models for inflammatory pain. Eur. J. Pain. 2006 ,10, 241-249 (Pubitemid 43255211)
54. Benedict J.W., Getty A.L., Wishart T.M., Gillingwater T.H., Pearce D.A. Protein product of CLN6 gene responsible for variant late-onset infantile neuronal ceroid lipofuscinosis interacts with CRMP-2. J. Neurosci. Res. 2009, 87, 2157-2166
55. Bisgaard C.F. et al. Proteomic investigation of the ventral rat hippocampus links DRP-2 to escitalopram treatment resistance and SNAP to stress resilience in the chronic mild stress model of depression. J. Mol. Neurosci. 2007, 32, 132-144 (Pubitemid 47460449)
56. Fujisawa H. et al. Involvement of post-translational modification of neuronal plasticity-related proteins in hyperalgesia revealed by a proteomic analysis. Proteomics. 2008, 8, 1706-1719 (Pubitemid 351580214)
57. Zhang F., Wang S., Signore A.P., & Chen,J. Neuroprotective effects of leptin against ischemic injury induced by oxygen-glucose deprivation and transient cerebral ischemia. Stroke. 2007, 38, 2329-2336 (Pubitemid 47457577)